Engineered compact crispr-cas12f system
OwnerWeixin TANG, Siyuan ZOU +1inventors
InventorsWeixin TANG, Siyuan ZOU, Tong WU
Life of this patent
Estimating the term…
Abstract
The current disclosure relates to new compact Cas12f CRISPR/Cas systems with improved activities, such as improved endonuclease activity. Aspects of the disclosure relate to engineered AsCas12f polypeptides comprising one or more amino acid substitutions relative to SEQ ID NO: 1, engineered CRISPR/Cas system ancillary component oligonucleotides such as sgRNA-v2, and polynucleotides encoding said polypeptides and/or functional RNA species. Also disclosed are vectors, compositions, and methods comprising and/or comprising use of the same.
Claims36
An engineered AsCas12f polypeptide comprising, one or more amino acid substitutions relative to a wild-type (WT) AsCas12f polypeptide represented by SEQ ID NO:
- 1, wherein the substitution increases affinity of the engineered AsCas12f protein to nucleic acids relative to WT AsCas12f.
(canceled)
6-13. (canceled)
15-22. (canceled)
(canceled)
26-28. (canceled)
30-34. (canceled)
37-39. (canceled)
An engineered AsCas12f structure-guided single guide RNA (sgRNA) comprising an oligonucleotide sequence that is truncated relative to a WT AsCas12f sgRNA as represented by SEQ ID NOs:
- 17 or 18.
43-45. (canceled)
47-57. (canceled)
59-61. (canceled)
(canceled)
65-72. (canceled)
(canceled)
77-78. (canceled)
80-84. (canceled)
Dependencies are inferred from the claim text.